Hormonal

Glucagon

Also known as: GlucaGen, Baqsimi

FDA Approved
Share:

Key Facts: Glucagon

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - Hypoglycemia and diagnostic
Administration
Injection, intranasal, or auto-injector
Typical Dose
Limited community data available
Frequency
See research protocols
Duration
Single dose emergency use
Also Known As
GlucaGen, Baqsimi

Mechanism of Action

Glucagon binds the glucagon receptor (GCGR), a seven-transmembrane G-protein-coupled receptor concentrated in the liver. The receptor couples to Gs, which switches on adenylate cyclase and floods the cell with the second messenger cAMP, activating protein kinase A (PKA). PKA then drives two pathways at once: it ramps up glycogenolysis (breaking glycogen back down into glucose) and gluconeogenesis (making fresh glucose), in part by activating enzymes like PEPCK and glucose-6-phosphatase. The net effect is the liver dumping glucose into the bloodstream. Glucagon and insulin work as an opposing pair to keep blood sugar in a tight range.

Research Summary

Glucagon's physiology and clinical role are textbook-settled, not experimental. It is FDA-approved and widely used as the standard rescue agent for severe hypoglycemia, and newer ready-to-use formulations (a nasal powder and stable liquid auto-injectors) have made it far easier for non-medical bystanders to give in an emergency. Receptor-level studies, including GCGR knockout mouse work, confirm that glucagon signaling through GCGR/PKA controls hepatic glucose output, and chronic glucagon excess (hyperglucagonemia) is linked to worse glucose control in diabetes. That last point is exactly why glucagon-receptor biology now sits at the center of next-generation metabolic drugs: several investigational obesity and diabetes agents (such as dual and triple incretin agonists) deliberately engage GCGR to boost energy expenditure. So beyond the established rescue use, glucagon is a hot target in current metabolic drug research.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosing

Community experience

Common Dose

Limited community data available

Range

See research dosing

Frequency

See research protocols

Research Dosing

Scientific studies

Emergency dosing

Doses from Studies

Duration

Single dose emergency use

Administration

Injection, intranasal, or auto-injector

Timing & Administration

Best Time to Take

Morning

Follow specific protocol

Food Recommendation

Take on empty stomach

Why This Timing?

Metabolic peptides often work best when taken in the morning to support daytime energy expenditure.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Nausea (up to 35%)
  • Vomiting
  • Headache
  • Hypertension
  • Tachycardia
  • Allergic reactions
  • Rebound hypoglycemia
  • CONTRAINDICATED with pheochromocytoma
  • FDA approved

References

Research This Peptide Further

Frequently Asked Questions

What does Glucagon do?

Glucagon is insulin's counterweight, a 29-amino-acid peptide hormone secreted by the alpha cells of the pancreas that raises blood sugar instead of lowering it. When glucose drops, glucagon tells the liver to break down stored glycogen and make new glucose, pushing blood sugar back up. Medically it is the emergency rescue treatment for severe hypoglycemia (the kind that knocks out a person with diabetes), available as injectable kits and a nasal-spray form, and it is also used in some diagnostic imaging to relax the gut.

How does Glucagon work?

Glucagon binds the glucagon receptor (GCGR), a seven-transmembrane G-protein-coupled receptor concentrated in the liver. The receptor couples to Gs, which switches on adenylate cyclase and floods the cell with the second messenger cAMP, activating protein kinase A (PKA). PKA then drives two pathways at once: it ramps up glycogenolysis (breaking glycogen back down into glucose) and gluconeogenesis (making fresh glucose), in part by activating enzymes like PEPCK and glucose-6-phosphatase. The net effect is the liver dumping glucose into the bloodstream. Glucagon and insulin work as an opposing pair to keep blood sugar in a tight range.

Is Glucagon FDA approved?

Yes, Glucagon is FDA approved. FDA Approved - Hypoglycemia and diagnostic

What are the side effects of Glucagon?

Reported side effects include: Nausea (up to 35%), Vomiting, Headache, Hypertension, Tachycardia. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Glucagon?

Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Injection, intranasal, or auto-injector. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Glucagon or used in similar applications.

Octreotide

FDA

Octreotide is a synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It shuts down excess growth hormone, so it is a frontline FDA-approved drug for acromegaly, and it also tames the flushing and diarrhea of hormone-secreting carcinoid and other neuroendocrine tumors. This is real, approved medicine with decades of clinical data behind it, sold as Sandostatin (injectable, since 1988), Sandostatin LAR (monthly depot), and Mycapssa (oral capsule, approved 2020).

Hormonal

Pasireotide

FDA

Pasireotide (brand name Signifor) is a second-generation somatostatin analog, a cyclic six-amino-acid peptide engineered to hit more receptor subtypes than octreotide or lanreotide. Its standout use is Cushing's disease, where it was the first drug FDA-approved (2012) to directly target the pituitary tumor driving cortisol excess, and it is also approved for acromegaly that resists first-line analogs. The catch is real and well known: it raises blood sugar in most patients, so it is a powerful but high-maintenance option.

Hormonal

Insulin

FDA

Insulin is the body's main blood-sugar-lowering hormone, a 51-amino-acid protein made of two chains (a 21-residue A-chain and a 30-residue B-chain) held together by disulfide bonds. Secreted by the beta cells of the pancreas, it tells the liver, muscle, and fat to take up glucose and store energy. Discovered in 1921 and first given to a patient in January 1922, it remains one of the most consequential drugs in medicine and is the cornerstone of treatment for type 1 and many cases of type 2 diabetes.

Hormonal

Oxytocin

FDA

Oxytocin is a 9-amino-acid hormone made in the hypothalamus, famous as the chemistry behind labor contractions, breastfeeding, and social bonding. As an injectable drug it is FDA-approved to induce labor and control postpartum bleeding, but the intranasal 'love hormone' versions sold for trust, anxiety, and autism are experimental and the human results are genuinely mixed. The hype runs well ahead of the evidence.

Hormonal

Gonadorelin

FDA

Gonadorelin is a synthetic copy of natural GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that tells the pituitary to release LH and FSH. It is FDA-approved for evaluating pituitary function and has historical use in inducing ovulation. In the peptide world it is mostly used off-label to keep the testes working during testosterone replacement, and the catch is that timing matters enormously: pulse it and you stimulate, give it continuously and you shut the system down.

Hormonal

Leuprolide

FDA

Leuprolide (brand name Lupron) is a synthetic GnRH agonist, a modified peptide about 20 times more potent than natural GnRH, and it is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The clever part is counterintuitive: it works by overstimulating the GnRH system so hard that the pituitary shuts down sex hormone production. It is a real, long-established prescription drug, not a research peptide, and it carries meaningful side effects from the low-hormone state it creates.

Hormonal

Want updates on Glucagon research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.